Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.58 |
| ▸ | BRAF | P15056 | 8/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637015 | 0.94 | MAPK14 (0.59) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL27960647 | 0.85 | MAPT (0.48) | MAPK14BRAFMAPTGSK3ALYN | |
| SCHEMBL6642300 | 0.85 | MAPK14 (0.59) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL6637183 | 0.83 | MAPK14 (0.57) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL6637081 | 0.82 | MAPK14 (0.56) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL6662323 | 0.81 | MAPK14 (0.57) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL6668162 | 0.81 | MAPK14 (0.59) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL2209864 | 0.81 | MAPK14 (0.57) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL6637878 | 0.80 | MAPK14 (0.54) | MAPK14BRAFHSP90AA1MAPTRECQL | |
| SCHEMBL4087240 | 0.80 | MAPK14 (0.73) | MAPK14BRAFHSP90AA1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | claimed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | claimed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | claimed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | claimed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | claimed |
| US-6825184-B2 | FOR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | claimed |
| EP-1438048-A1 | 1,4-DISUBSTITUTED BENZO-FUSED UREA COMPOUNDS AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-21 | — | — | EP | claimed |
| WO-2003032989-A1 | 1,4-DISUBSTITUTED BENZO-FUSED UREA COMPOUNDS AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | SIGNAL PHARM LLC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3659599-B1 | 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE FOR USE IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME | SIGNAL PHARM LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3466423-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| US-6825184-B2 | FOR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | MTOR, TTK, BRCA1 | MAPK14 331/4885BRAF 220/4885HSP90AA1 685/4885 |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MAPK14 224/4885BRAF 69/4885HSP90AA1 553/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | MAPK14 474/4885BRAF 85/4885HSP90AA1 1024/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | MAPK14 583/4885BRAF 53/4885HSP90AA1 1310/4885 |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | MTOR, TTK, RICTOR | MAPK14 224/4885BRAF 69/4885HSP90AA1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.